-
The current situation of the development of biomedical technology innovation in China
Time of Update: 2020-09-14
is still a long way from developed countries; the world's scientific research landscape is changing significantly, with total global spending growing at an average annual rate of 6.7 per cent between 2001 and 2011.
-
The war in the managed canteen was filled with smoke
Time of Update: 2020-09-11
Hubei Puyang has a group meal company, registered capital of 10 million yuan, peak period custody of more than 20 canteen operations, development of more than ten years, experience the hardships and helplessness of the group meal industry, as well as according to the documents, the contract expired to recover.
-
A number of well-known pharmaceutical companies to be listed
Time of Update: 2020-08-18
public information shows that, in 1995, First Sound Pharmaceuticals, was established in 2007 as China's first bio- and chemical pharmaceutical company on the New York Stock Exchange, raising $226 million with a market value of more than $1 billion; -first-sound pharmaceuticalindustry focuses on tumor diseases (including cell therapy), central nervous system diseases and autoimmune diseases.
-
The total survival rate increased by more than twice, and then Ding Pharma's first tumor electric field treatment products on the market
Time of Update: 2020-08-16
"This innovative treatment for tumor electric field therapy has been shown to change the clinical treatment of glioblastoma, " said Liu Huilong, deputy director of oncology at the Seventh Medical Center of the PLA General Hospital.
-
Libang China and Belgium's Fast O Group signed a strategic cooperation
Time of Update: 2020-08-12
April 22, Libang China and Europe sealant and adhesive leading brand Belgian Express Group, signed a strategic cooperation agreement in Shanghai, the two sides will be in product technology and retai
-
medRxiv: Blood type A is more prone to COVID19
Time of Update: 2020-07-31
now, a new study by researchers at the University of Ulm in Germany, published in the journal medRxiv, focuses on how blood type distribution is linked to the geographic dynamics of the epidemic.
-
Health insurance trends as a supplement to health insurance
Time of Update: 2020-07-09
Unlike a few countries, such as the United States, most of the world's countries and regions have a broad coverage of social security model Under the broad coverage of health insurance, commercial hea
-
Litoximonostise reduces disease loss in RRMS patients
Time of Update: 2020-07-07
recently announced the results of the 59th annual meeting of the American Association of Neurologists (ANN) in Boston, Usa in the United States: rituximab treatment of recurrent-relief multiple scle
-
South Korea enacts pharmaceutical law to protect patents involving new drug applications and supplements
Time of Update: 2020-07-06
On October 16, 2007, Korea enacted a pharmaceutical law to comply with the Free Trade Agreement (FTA) between Korea and the United States and to protect patents relating to the application and suppl
-
Study: Down syndrome patients have genes to suppress cancer
Time of Update: 2020-07-05
the latest findings from geneticists at Johns Hopkins University School of Medicine in the United States that people with Down syndrome have genes that suppress cancer, making them far less likely t
-
FDA approves first superbug rapid blood detector
Time of Update: 2020-07-05
the U.S Food and Drug Administration approved a blood tester for "superbug" MRSA for clinical use February This is the first in the United States to be approved for clinical MRSA rapid detection
-
Ultragenyx announces positive data from its AAV gene therapy DTX401, a phase 1/2 confirmed study group for type Ia glycogenic storage disease
Time of Update: 2020-06-25
Ultragenyx Pharmaceuticals has announced its adenosic-related virus (AAV)-based gene therapy DTX401, a phase 1/2 study of DTX401 for the treatment of GSDIa Compared to the first two queues, all thre
-
Avon Pharmaceuticals Original NASH New Drug HPG1860 Approved by FDA Clinical Trials
Time of Update: 2020-06-17
"FDA's approval of the first phase of the HPG1860 clinical trial is an important milestone for Avon Pharmaceuticals In addition to NASH, the company's other original new drugs for HBV and HCC will con
-
There is also an excessive level of NDMA in metformin! FDA requires 5 companies to recall
Time of Update: 2020-06-15
The FDA announced that testing of the slow-release metformin drug found that some metformin products contained higher levels of NDMA than the body's acceptable daily intake as prescribed by regulators
-
FDA accepts new drug listing for brexanolone (SAGE-547) intravenous injection syltorapy for postpartum depression
Time of Update: 2020-06-11
recently, Sage Therapeutics announced that FDA (which has accepted the of new drugs (NDA) for the treatment of postpartum depression with brexanolone (SAGE-547) intravenous injections, and grant
